Fort Worth, TX – According to filings with the U.S. Securities and Exchange Commission, Sanara MedTech is raising $14,496,472.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Michael Mcneil played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Sanara MedTech
With our focus on improving patient outcomes with evidence-based healing solutions, Sanara MedTech Inc. develops, markets and distributes surgical, wound care and skin care products to physicians, hospitals, clinics and all post-acute care settings. We are constantly seeking long-term strategic partnerships with a focus on products that produce efficacious outcomes at a lower overall cost. Our primary products are sold in the North American advanced wound care and surgical tissue repair markets. Sanara MedTech sells and distributes CellerateRX Surgical Activated Collagen Powder to the surgical market and BIAKOS Antimicrobial Skin and Wound Cleanser, Irrigation Solution, and Wound Gel, HYCOL Hydrolyzed Collagen, and PULSAR II Advanced Wound Irrigation System (AWI) to the wound care market.

To learn more about Sanara MedTech, visit http://sanaramedtech.com/

Contact:
Michael Mcneil, Chief Financial Officer
817-529-2300
mmcneil@sanaramedtech.com
https://www.linkedin.com/in/mike-mcneil-19aa0514/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved